ZytuxTM is a biosimilar product with the generic name of Rituximab
and is used for treatment of some types of cancer. It is a chimeric monoclonal antibody against CD20 antigens presents
on surface of lymphocyte cells.
ZytuxTMis a genetically engineered human-mouse chimeric monoclonal antibody
produced by Chinese Hamster Ovary (CHO) cells in suspension and purified by some steps of chromatography. It is a fusion of the
light and heavy chain variable domains of a murine monoclonal anti-CD20 antibody and human kappa light-chain and gamma 1 heavy-chain
constant regions. Active ingredient of Zytux™, Rituximab, consists of two heavy chains of 451 amino acids and two light chains
of 213 amino acids, with an approximate molecular weight of 148 kDa. Rituximab binds to the target CD20 antigen via the variable
murine regions, while the remainder of the antibody interacts with human immune-effector mechanisms to kill the target cells.
ZytuxTM is supplied as a sterile, clear, colorless, preservative-free liquid
concentrate for intravenous (IV) infusion. It is provided in two dosages, 100 mg and 500 mg vials.
For more information visit us at www.zytux.com